Biovica International AB (publ) (STO:BIOVIC.B)
Sweden · Delayed Price · Currency is SEK 0.5300
+0.0060 (1.15%)
Aug 13, 2026, 5:29 PM CET
Biovica International AB Company Description
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia.
The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors.
It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Biovica International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Theis Kipling |
Contact Details
Address: Dag Hammarskjölds väg 54B Uppsala, Uppsala County 752 37 Sweden | |
| Phone | 46 1 84 44 48 30 |
| Website | biovica.com |
Stock Details
| Ticker Symbol | BIOVIC.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | May - April |
| Reporting Currency | SEK |
| ISIN Number | SE0008613731 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Theis Kipling | Chief Executive Officer |
| Anders Moren | Chief Financial Officer and Secretary |
| Hanna Ritzén | Senior Vice President of Global Marketing and Business Development |
| Henrik Winther D.V.M., Ph.D. | Head and Senior Vice President of Pharma Services |
| Hector Tamburini | Head of US Laboratory Operations, Regulatory and Quality |